Highest-materiality recent filing
TuHURA Q1 cash $6.3M; secures $50M credit facility; IFx-2.0 gets ODD in melanoma
Cash and equivalents $6.3M at March 31, 2026; net operating cash outflow $4.4M in Q1.
$50M revolving credit facility from Parkview (affiliate of largest stockholder) at 12% interest, matures April 2031.
TuHURA FY2025 cash $3.6M, R&D $20.5M; Phase 3 MCC trial ongoing; Kineta acquired
Cash $3.6M at Dec 31, 2025; additional $7.5M from 2025 registered direct offering received Q1 2026.
Nasdaq letter on Jan 29, 2026, for bid price <$1.00 for 35 consecutive days, violating Listing Rule 5550(a)(2).
TuHURA Biosciences prices $15.6M registered direct offering of stock and warrants in three tranches
TuHURA prices registered direct offering of 9.46M shares and Series A/B warrants at $1.65/unit; warrants exercisable at $1.95 after six months.
TuHURA reports Q3 R&D $4.9M, cash burn $22.1M; Phase 3 MCC trial underway
Phase 3 IFx-2.0 trial for MCC under SPA enrollment ongoing; topline results expected Q1 2027.
TuHURA starts Phase 3 IFx-2.0 trial, acquires TBS-2025, defers IFx-3.0
Initiated Phase 3 trial of IFx-2.0 + Keytruda in 1L Merkel cell carcinoma under FDA SPA for accelerated approval.
TuHURA secures $3M bridge loan at 3% monthly interest, secured by ImmuneFx patents
Initial $1.5M advance from Matthew Nachtrab Revocable Trust on Oct 27, 2025; up to $3M total available.
TuHURA Q2 R&D $4.9M, initiates Phase 3 IFx-2.0 trial, acquires Kineta VISTA mAb
Completed acquisition of Kineta; VISTA mAb (TBS-2025) Phase 2 AML trial planned for 2H 2025.
Kineta acquisition closed; Q1 2025 financials show $1.7M net loss and $13.2M deficit
Cash $304K, total liabilities $14M, stockholders' deficit $13.2M as of March 31, 2025.
TuHURA completes Kineta acquisition, adds Phase 2 VISTA mAb TBS-2025
Each Kineta share converted into 0.185298 TuHURA shares; ~2.87M shares issued at closing, plus up to ~1.13M additional shares subject to six-month adjustment.
TuHURA and Kineta stockholders approve merger; authorized shares increased to 200M
TuHURA shareholders approved all proposals: authorized shares increased from 75M to 200M, reincorporation to Delaware.
TuHURA raises $12.6M in private placement, $3M from warrants, tied to Phase 3 & merger milestones
Total offering $12.6M (4.76M shares + warrants at $2.65/unit). Initial closing $2.23M.
TuHURA amends Kineta merger; revises consideration, extends end date to June 30, 2025
First Amendment revises merger consideration: Initial Stock Consideration based on $16.5M less adjustments at $5.7528/share.
TuHURA to acquire Kineta in stock/cash merger; $35M concurrent financing required
Consideration per Kineta share: initial stock based on $15M pool, delayed stock based on $5M, plus cash and contingent asset payment rights.
TuHURA plans IFx-2.0 Phase 3 trial under SPA; signs non-binding LOI to acquire Kineta's KVA12123
IFx-2.0 Phase 3 accelerated approval trial in first-line MCC to start H1 2025 under FDA SPA, with ORR primary and PFS secondary endpoints.
TuHURA posts $15.7M net loss through Q3 2024; convertible debt rises to $24.4M
Net loss of $15.7M for nine months ended Sep 30, 2024 vs $26.6M prior year (prior year included $16.2M IPR&D charge).
Kintara completes reverse merger with TuHURA; renamed TuHURA Biosciences, trades as HURA
Merger closed Oct 18, 2024; Kintara securityholders own ~2.85% of combined entity (or 5.45% if CVR milestone met).
Kintara sets Oct 17 record date for CVRs; TuHURA merger expected Oct 18
Record date of Oct 17, 2024 for CVR issuance to Kintara stockholders.
Kintara stockholders approve TuHURA merger; FY2024 net loss $8.32M
Stockholders approved merger with TuHURA on Oct 4, 2024; closing expected mid-October 2024.
TuHURA reports H1 2024 net loss $10.1M, cash $12.3M; merger with Kintara on track for Q4 2024
Net loss $10.1M for six months ended June 30, 2024; prior period loss $22.1M incl $16.2M IPR&D charge.
Kintara shareholders approve merger proposals; charter increase and reincorporation fail
Nasdaq Proposal to approve merger share issuance passed: 26.75M for, 1.18M against.
TuHURA waives requirement for Kintara stockholder vote on reincorporation from Nevada to Delaware.
Kintara adjourns special meeting; merger vote faces shortfall, adjourned to Oct 4
Special meeting adjourned to Oct 4, 2024 at 9:00 am EST; voting threshold not reached for Proposals 3 & 5.
Kintara adjourns special meeting to Oct 4 due to insufficient votes on merger-related proposals
Special Meeting on Sept 20, 2024 adjourned to Oct 4, 2024 because insufficient votes on Proposal 3 (increase authorized shares to 400M) and Proposal 5 (reincorporation to Delaware).
Kintara says merger vote threshold not yet met; stockholders urged to vote by Sept 19
Special meeting on Sept 20; votes must be cast by 11:59pm ET Sept 19 to count.
Special Meeting on Sept 20, 2024 to vote on TuHURA merger; existing holders get 5.45% of combined co. plus CVRs.
Kintara warns of possible bankruptcy if TuHURA merger fails; special meeting Sept 20
Special meeting to approve merger with TuHURA set for Sept 20, 2024; vote deadline Sept 19 at 11:59 p.m. ET.
the Separation Agreement confirms that Mr. Yamashita’s employment with TuHURA terminated effective December 16, 2024
On March 7, 2025, the Board of Directors (the “Board”) of TuHURA Biosciences, Inc. (the “Company”) increased the size of the Board from five members to six members and appointed Dr. Craig Tendler to the Board, effective as of March 10, 2025, to serve as a director until the Company’s 2025 Annual Meeting of Stockholders and until his successor has been duly elected and qualified or until his earlier death, resignation or removal.
on November 20, 2023, Dennis Brown was terminated from his position as the Company’s Chief Scientific Officer, effective immediately.
On May 30, 2023, Scott Praill resigned from his position as Chief Financial Officer of Kintara Therapeutics, Inc. (the “Company”), effective May 31, 2023.
On June 1, 2023, the Company’s Board of Directors (the “Board”) appointed Robert E. Hoffman, the current President, Chief Executive Officer, and Chairman of the Board of the Company, to succeed Mr. Praill as the Company’s interim Chief Financial Officer.
On May 20, 2022, Kintara Therapeutics, Inc. (the “Company”) and Saiid Zarrabian, the Company’s Head of Strategic Partnerships and a member of the Board of Directors (the “Board”) of the Company, mutually agreed that Mr. Zarrabian would step down from his role as Head of Strategic Partnerships and as a member of the Board, effective as of May 23, 2022 (the “Separation Date”) to pursue other opportunities.
On February 4, 2022, Keith Murphy submitted his resignation from the Board of Directors (the “Board”) of Kintara Therapeutics, Inc. (the “Company”), effective immediately.
On November 8, 2021, the Board of Directors (the “Board”) of Kintara Therapeutics, Inc. (the “Company”) appointed Robert E. Hoffman, the then current Chairman of the Board, to succeed Saiid Zarrabian as President and Chief Executive Officer of the Company.
on November 8, 2021, the Board and Mr. Zarrabian mutually agreed that Mr. Zarrabian would immediately transition into the role of Head of Strategic Partnerships.
On October 25, 2021, Kintara Therapeutics, Inc. (the “Company”) and John Liatos, the Company’s Senior Vice President, Business Development, mutually agreed that Mr. Liatos would step down from his role as Senior Vice President, Business Development effective immediately to pursue other opportunities.
Max materiality 0.90 · Median 0.60 · Most common event other_material